VCYT Quote, Financials, Valuation and Earnings

Fonar has a net margin of 13.08% compared to Veracyte's net margin of 12.56%. Veracyte's return on equity of -0.84% beat Fonar's return on equity of 6.13%.

Veracyte has a consensus price target of $43.22, signalling upside risk potential of 3.13%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Veracyte has a beta of 1.706, which suggesting that the stock is 70.591% more volatile than S&P 500. In comparison Fonar has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.214%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $115.9M, which are larger than Fonar quarterly revenues of $25M. Veracyte's net income of $15.2M is higher than Fonar's net income of $3.1M. Notably, Veracyte's price-to-earnings ratio is -- while Fonar's PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 7.48x versus 0.95x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

OncoCyte has a net margin of 13.08% compared to Veracyte's net margin of -11733.04%. Veracyte's return on equity of -0.84% beat OncoCyte's return on equity of -211.42%.

Veracyte has a consensus price target of $43.22, signalling upside risk potential of 3.13%. On the other hand OncoCyte has an analysts' consensus of $4.13 which suggests that it could grow by 74.05%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

Veracyte has a beta of 1.706, which suggesting that the stock is 70.591% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.313%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $115.9M, which are larger than OncoCyte quarterly revenues of $115K. Veracyte's net income of $15.2M is higher than OncoCyte's net income of -$13.5M. Notably, Veracyte's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 7.48x versus 36.03x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 13.08% compared to Veracyte's net margin of -209.38%. Veracyte's return on equity of -0.84% beat ProPhase Labs's return on equity of -59.59%.

Veracyte has a consensus price target of $43.22, signalling upside risk potential of 3.13%. On the other hand ProPhase Labs has an analysts' consensus of -- which suggests that it could grow by 2124.63%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

Veracyte has a beta of 1.706, which suggesting that the stock is 70.591% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.304, suggesting its less volatile than the S&P 500 by 130.392%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $115.9M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Veracyte's net income of $15.2M is higher than ProPhase Labs's net income of -$6.6M. Notably, Veracyte's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 7.48x versus 1.21x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 13.08% compared to Veracyte's net margin of -56.4%. Veracyte's return on equity of -0.84% beat XWELL's return on equity of -71.82%.

Veracyte has a consensus price target of $43.22, signalling upside risk potential of 3.13%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 372.97%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

Veracyte has a beta of 1.706, which suggesting that the stock is 70.591% more volatile than S&P 500. In comparison XWELL has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.765%.

Veracyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Veracyte quarterly revenues are $115.9M, which are larger than XWELL quarterly revenues of $8.4M. Veracyte's net income of $15.2M is higher than XWELL's net income of -$4.8M. Notably, Veracyte's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte is 7.48x versus 0.19x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.